Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could have a promising ...

According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...

While Zepbound leads today, the next potential rally may be sparked by Orforglipron, Eli Lilly's small-molecule oral GLP-1. Phase 3 obesity data is expected in the third quarter, with a launch ...

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses of its blockbuster weight loss medicine Zepbound. The company pledged ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access without insurance barriers.

Eli Lilly announced on Monday it will soon make the two highest doses of its popular weight-loss drug Zepbound available for self-paying customers on its website. Starting in August, 12.5 ...

UBS has maintained its Buy rating on Eli Lilly, setting a price target at $1,050.00, with particular attention on the upcoming Phase 3 SURPASS-CVOT trial comparing Mounjaro to Trulicity in type 2 ...

U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on its website LillyDirect, with shipments starting in early August.